Assembly Biosciences, Inc. Payments to Acquire Debt Securities, Available-for-sale
Assembly Biosciences, Inc. (ASMB) reported Payments to Acquire Debt Securities, Available-for-sale of $208.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-13
- Assembly Biosciences, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $145.84M, a 733.06% increase year-over-year.
- Assembly Biosciences, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $62.96M, a 217.26% increase year-over-year.
- Assembly Biosciences, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $11.55M, a 71.75% decline year-over-year.
- Assembly Biosciences, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $180.93M, a 1129.81% increase year-over-year.
- Assembly Biosciences, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $229.83M, a 153.96% increase from fiscal 2024.
- Assembly Biosciences, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $90.50M, a 32.42% decline from fiscal 2023.
- Assembly Biosciences, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $133.92M, a 385.52% increase from fiscal 2022.
- Assembly Biosciences, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $27.58M, a 82.81% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $145.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $208.80M 10-Q · filed 2026-08-13 | $220.35M derived: sum of 3 quarters · filed 2026-08-13 | $401.28M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $62.96M 10-Q · filed 2026-05-07 | $74.52M derived: sum of 2 quarters · filed 2026-05-07 | $255.44M derived: sum of 3 quarters · filed 2026-05-07 | $272.95M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $11.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $192.48M derived: sum of 2 quarters · filed 2026-03-19 | $209.99M derived: sum of 3 quarters · filed 2026-08-13 | $229.83M 10-K · filed 2026-03-19 |
| 2025-09-30 | $180.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $198.44M derived: sum of 2 quarters · filed 2026-08-13 | $218.28M 10-Q · filed 2025-11-10 | $259.18M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $17.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $37.35M 10-Q · filed 2026-08-13 | $78.25M derived: sum of 3 quarters · filed 2026-08-13 | $92.96M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $19.85M 10-Q · filed 2026-05-07 | $60.74M derived: sum of 2 quarters · filed 2026-05-07 | $75.45M derived: sum of 3 quarters · filed 2026-05-07 | $106.63M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $40.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $55.61M derived: sum of 2 quarters · filed 2026-03-19 | $86.79M derived: sum of 3 quarters · filed 2026-03-19 | $90.50M 10-K · filed 2026-03-19 |
| 2024-09-30 | $14.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $45.89M derived: sum of 2 quarters · filed 2025-11-10 | $49.60M 10-Q · filed 2025-11-10 | $157.91M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $31.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $34.89M 10-Q · filed 2025-08-06 | $143.20M derived: sum of 3 quarters · filed 2025-08-06 | $145.85M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $3.71M 10-Q · filed 2025-05-08 | $112.02M derived: sum of 2 quarters · filed 2025-05-08 | $114.67M derived: sum of 3 quarters · filed 2025-05-08 | $137.64M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $108.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $110.96M derived: sum of 2 quarters · filed 2025-03-20 | $133.92M derived: sum of 3 quarters · filed 2025-03-20 | $133.92M 10-K · filed 2025-03-20 |
| 2023-09-30 | $2.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $25.61M derived: sum of 2 quarters · filed 2024-11-07 | $25.61M 10-Q · filed 2024-11-07 | $34.38M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $22.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $22.96M 10-Q · filed 2024-08-08 | $31.73M derived: sum of 3 quarters · filed 2024-08-08 | $34.69M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | $8.76M derived: sum of 2 quarters · filed 2024-05-08 | $11.73M derived: sum of 3 quarters · filed 2024-05-08 | $23.63M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $8.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $11.73M derived: sum of 2 quarters · filed 2024-03-28 | $23.63M derived: sum of 3 quarters · filed 2024-03-28 | $27.58M 10-K · filed 2024-03-28 |
| 2022-09-30 | $2.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $14.87M derived: sum of 2 quarters · filed 2023-11-08 | $18.82M 10-Q · filed 2023-11-08 | $71.79M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $11.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $15.85M 10-Q · filed 2023-08-09 | $68.82M derived: sum of 3 quarters · filed 2023-08-09 | $91.50M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $3.95M 10-Q · filed 2023-05-04 | $56.92M derived: sum of 2 quarters · filed 2023-05-04 | $79.60M derived: sum of 3 quarters · filed 2023-05-04 | $115.18M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $52.97M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $75.65M derived: sum of 2 quarters · filed 2023-03-22 | $111.23M derived: sum of 3 quarters · filed 2023-03-22 | $160.45M 10-K · filed 2023-03-22 |
| 2021-09-30 | $22.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $58.27M derived: sum of 2 quarters · filed 2022-11-08 | $107.48M 10-Q · filed 2022-11-08 | $147.65M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $35.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $84.80M 10-Q · filed 2022-08-09 | $124.97M derived: sum of 3 quarters · filed 2022-08-09 | $233.75M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $49.21M 10-Q · filed 2022-05-12 | $89.38M derived: sum of 2 quarters · filed 2022-05-12 | $198.16M derived: sum of 3 quarters · filed 2022-05-12 | $198.16M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $40.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $148.95M derived: sum of 2 quarters · filed 2022-03-11 | $148.95M derived: sum of 3 quarters · filed 2022-03-11 | $193.19M 10-K · filed 2022-03-11 |
| 2020-09-30 | $108.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $108.78M derived: sum of 2 quarters · filed 2021-11-04 | $153.02M 10-Q · filed 2021-11-04 | $285.03M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | -$2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $44.24M 10-Q · filed 2021-08-05 | $176.25M derived: sum of 3 quarters · filed 2021-08-05 | $231.91M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $44.24M 10-Q · filed 2021-05-06 | $176.25M derived: sum of 2 quarters · filed 2021-05-06 | $231.91M derived: sum of 3 quarters · filed 2021-05-06 | $276.55M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $132.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $187.67M derived: sum of 2 quarters · filed 2021-02-25 | $232.30M derived: sum of 3 quarters · filed 2021-02-25 | $281.33M 10-K · filed 2021-02-25 |
| 2019-09-30 | $55.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $100.30M derived: sum of 2 quarters · filed 2020-11-05 | $149.33M 10-Q · filed 2020-11-05 | $218.24M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $44.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $93.67M 10-Q · filed 2020-08-05 | $162.58M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | $49.03M 10-Q · filed 2020-05-08 | $117.94M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $68.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $183.94M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $115.03M 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $48.23M 10-K · filed 2020-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |